Somewhat Positive Media Coverage Somewhat Unlikely to Affect Shire (SHPG) Share Price
Media stories about Shire (NASDAQ:SHPG) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Shire earned a news impact score of 0.20 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 44.9662601968132 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- As Shire Plc (SHPG) Market Value Rose, Accipiter Capital Management Has Lifted by $1.98 Million Its Stake; Halcyon … – Hill Country Times (hillcountrytimes.com)
- Md Sass Investors Services Lowered By $23.03 Million Its Shire Plc (SHPG) Position; 3 Bullish Analysts Covering … – Hill Country Times (hillcountrytimes.com)
- Shire PLC (SHPG) Receives Average Recommendation of “Hold” from Brokerages (americanbankingnews.com)
- Zacks: Brokerages Anticipate Shire PLC (SHPG) to Post $3.86 EPS (americanbankingnews.com)
- Equities Analysts Set Expectations for Shire PLC’s FY2022 Earnings (SHPG) (americanbankingnews.com)
SHPG has been the topic of a number of research reports. ValuEngine upgraded shares of Shire from a “hold” rating to a “buy” rating in a research report on Thursday, October 26th. Stifel Nicolaus restated a “buy” rating and set a $245.00 target price on shares of Shire in a research report on Sunday, October 8th. Royal Bank of Canada restated a “buy” rating and set a $213.00 target price on shares of Shire in a research report on Monday, October 2nd. FBR & Co initiated coverage on shares of Shire in a research report on Thursday, October 19th. They set a “buy” rating and a $201.00 target price on the stock. Finally, Cantor Fitzgerald set a $222.00 target price on shares of Shire and gave the company a “buy” rating in a research report on Thursday, November 16th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $212.18.
Shire (NASDAQ:SHPG) last announced its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, beating analysts’ consensus estimates of $3.64 by $0.17. The business had revenue of $3.70 billion for the quarter. Shire had a net margin of 10.95% and a return on equity of 14.41%. The business’s revenue was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.17 earnings per share. equities analysts anticipate that Shire will post 15 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/01/16/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-shire-shpg-share-price.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.